drugset / Trial / NCT02181985
Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)
RandomizedParallel-groupOpen-labelTreatment
Summary
The objective of ASSENT 3 was to evaluate the safety and efficacy of full dose tenecteplase with heparin sodium (group A), full dose tenecteplase combined with enoxaparin (group B) and half dose tenecteplase combined with abciximab and heparin sodium (group C).
Timeline
- Start
- 2000-05
- Primary completion
- 2001-04
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abciximab | Monoclonal antibody | — | — |
| Subject | Enoxaparin sodium | Other / unclassified | — | — |
| Subject | Heparin | Other / unclassified | — | — |
| Subject | Tenecteplase | Protein / enzyme biologic | — | — |